Induction of HLA-DP4–Restricted Anti-Survivin Th1 and Th2 Responses Using an Artificial Antigen-Presenting Cell

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Cancer Research

• Publication date

  2011-06-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-10-3083PMID 21705450PMCID PMC3156899
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Establishment of Antitumor Memory in Humans Using in Vitro–Educated CD8+ T Cells

  2011cited by this paper
• A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles.

  2010influential reference
• Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients

  2009cited by this paper
• A Chronic Need for IL-21

  2009cited by this paper
• Survivin: a new target for anti-cancer therapy.

  2009cited by this paper
• The precursors of memory: models and controversies

  2009cited by this paper
• Visualizing Antigen Specific CD4+ T Cells using MHC Class II Tetramers

  2009cited by this paper
• Multiple roles for CD4+ T cells in anti‐tumor immune responses

  2008cited by this paper
• Dissociation of Its Opposing Immunologic Effects Is Critical for the Optimization of Antitumor CD8+ T-Cell Responses Induced by Interleukin 21

  2008cited by this paper
• Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

  2008cited by this paper
• Class II major histocompatibility complex tetramer staining: progress, problems, and prospects

  2008cited by this paper
• IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes.

  2008cited by this paper
• Survivin, cancer networks and pathway-directed drug discovery

  2008cited by this paper
• Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients1

  2008influential reference
• IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.

  2008cited by this paper
• Targeting survivin in cancer therapy: fulfilled promises and open questions.

  2007cited by this paper
• Differential expression of survivin splice isoforms in medulloblastomas

  2007cited by this paper
• The Universal Character of the Tumor-Associated Antigen Survivin

  2007cited by this paper
• Alternative splice variants of survivin as potential targets in cancer.

  2007cited by this paper
• Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell

  2007cited by this paper
• Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity.

  2006influential reference
• Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin

  2006cited by this paper
• Survivin, a cancer target with an emerging role in normal adult tissues

  2006cited by this paper
• Cooperation between CD4+ and CD8+ T cells: when, where, and how.

  2006cited by this paper
• Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia.

  2006cited by this paper
• Scanning the HIV Genome for CD4+ T Cell Epitopes Restricted to HLA-DP4, the Most Prevalent HLA Class II Molecule1

  2006influential reference
• Molecular Analysis of Survivin Isoforms

  2006cited by this paper
• Efficient Presentation of Naturally Processed HLA Class I Peptides by Artificial Antigen-Presenting Cells for the Generation of Effective Antitumor Responses

  2006cited by this paper
• Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients

  2005cited by this paper
• Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

  2005cited by this paper
• Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC).

  2005cited by this paper
• Survivin splice variants regulate the balance between proliferation and cell death

  2005cited by this paper
• IL-21 Influences the Frequency, Phenotype, and Affinity of the Antigen-Specific CD8 T Cell Response1

  2005cited by this paper
• HLA‐B35‐restricted immune responses against survivin in cancer patients

  2004cited by this paper
• Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer

  2004cited by this paper
• Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer

  2004cited by this paper
• HLA-DP4 presents an immunodominant peptide from the RSV G protein to CD4 T cells.

  2004influential reference
• Full-length dominant-negative survivin for cancer immunotherapy.

  2003cited by this paper
• Transcriptional expression of survivin and its splice variants in brain tumors in humans.

  2003cited by this paper
• Induction of antitumour immunity using survivin peptide‐pulsed dendritic cells in a murine lymphoma model

  2003cited by this paper
• Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.

  2003cited by this paper
• Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer.

  2003cited by this paper
• An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.

  2002cited by this paper
• HLA-DP4, the Most Frequent HLA II Molecule, Defines a New Supertype of Peptide-Binding Specificity1

  2002cited by this paper
• Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.

  2001cited by this paper
• CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production

  2001cited by this paper
• A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.

  2000influential reference
• IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.

  1998cited by this paper
• Expression of costimulatory molecules in human leukemias.

  1996cited by this paper
• Irreversible association of peptides with class II MHC molecules in living cells

  1992cited by this paper

• Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells

  2024cites this paper
• Stealth in non-tuberculous mycobacteria: clever challengers to the immune system.

  2024cites this paper
• MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy

  2022cites this paper
• Design of artificial cells: artificial biochemical systems, their thermodynamics and kinetics properties

  2022cites this paper
• HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy

  2019influential citation
• Chaperones of the class I peptide-loading complex facilitate the constitutive presentation of endogenous antigens on HLA-DP84GGPM87.

  2019cites this paper
• Mechanisms underlying the lack of endogenous processing and CLIP-mediated binding of the invariant chain by HLA-DP84Gly

  2018cites this paper
• A Subset of Human Autoreactive CD1c-Restricted T Cells Preferentially Expresses TRBV4-1+ TCRs

  2018cites this paper
• HLA-DP84Gly constitutively presents endogenous peptides generated by the class I antigen processing pathway

  2017cites this paper
• Key Residues at Third CDR3β Position Impact Structure and Antigen Recognition of Human Invariant NK TCRs

  2017cites this paper
• Modulation of Dendritic Cells by Nanotechnology-Based Immunotherapeutic Strategies.

  2016cites this paper
• Artificial antigen-presenting cells expressing AFP158-166 peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes

  2016cites this paper
• Creation of an engineered APC system to explore and optimize the presentation of immunodominant peptides of major allergens

  2016cites this paper
• Survivin: a unique target for tumor therapy

  2016cites this paper
• Mouse and Human CD1d-Self-Lipid Complexes Are Recognized Differently by Murine Invariant Natural Killer T Cell Receptors

  2016cites this paper
• Proteomic Profiling of Serum Derived Exosomes from Prostate Cancer Patients

  2016cites this paper
• This information is current as Human Invariant NK TCRs ofImpact Structure and Antigen Recognition Position β Key Residues at Third CDR 3

  2016cites this paper
• Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma

  2015cites this paper
• Adoptive T Cell Therapy Targeting CD1 and MR1

  2015cites this paper
• Specific Roles of Each TCR Hemichain in Generating Functional Chain-Centric TCR

  2015cites this paper
• Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy

  2014cites this paper
• Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors

  2014cites this paper
• Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy.

  2014cites this paper
• Survivin as a Cancer Vaccine Target

  2014cites this paper
• Dendritic cell-based nanovaccines for cancer immunotherapy.

  2013cites this paper
• Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients

  2013cites this paper
• Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

  2012cites this paper
• Generating Functional Chain-Centric TCR Specific Roles of Each TCR Hemichain in

  year unknowncites this paper
• Biologics: Targets and Therapy Dovepress Localization and Upregulation of Survivin in Cancer Health Disparities: a Clinical Perspective

  year unknowncites this paper